Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.59 |
| ▸ | BACE1 | P56817 | 4/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
| ▸ | TUBB | P07437 | 1/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608770 | 0.90 | BACE1 (0.70) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL608769 | 0.90 | BACE1 (0.70) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL15781551 | 0.85 | MAPT (0.74) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL29332643 | 0.85 | GSK3B (0.79) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL13358175 | 0.85 | GSK3B (0.71) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL16884580 | 0.85 | GSK3B (0.71) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL9972320 | 0.84 | HDAC1 (0.67) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL13358184 | 0.84 | HDAC1 (0.67) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL16093013 | 0.84 | FOS (0.51) | HDAC1HDAC2HDAC8BACE1GSK3B | |
| SCHEMBL13446382 | 0.83 | MMP2 (0.74) | HDAC1HDAC2HDAC8BACE1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-22 | — | — | US | disclosed |
| US-9907786-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-06 | — | — | US | disclosed |
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-08-03 | — | — | US | disclosed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | Ions Pharmaceutical S.à r.I. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-9402834-B2 | Human therapeutic agents | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-08-02 | — | — | US | disclosed |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | HDAC1 345/4885HDAC2 608/4885HDAC8 521/4885 |
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | HDAC1 1292/4885HDAC2 445/4885HDAC8 855/4885 |
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | HDAC1 1292/4885HDAC2 445/4885HDAC8 855/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | HDAC1 1012/4885HDAC2 462/4885HDAC8 745/4885 |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | HDAC1 1292/4885HDAC2 445/4885HDAC8 855/4885 |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | HDAC1 1292/4885HDAC2 445/4885HDAC8 855/4885 |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | HDAC1 1292/4885HDAC2 445/4885HDAC8 855/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | HDAC1 345/4885HDAC2 608/4885HDAC8 521/4885 |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | HDAC1 1249/4885HDAC2 736/4885HDAC8 797/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | HDAC1 1292/4885HDAC2 445/4885HDAC8 855/4885 |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | HDAC1 1249/4885HDAC2 736/4885HDAC8 797/4885 |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | HDAC1 1249/4885HDAC2 736/4885HDAC8 797/4885 |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | L1CAM, LY96, GMFG | HDAC1 1136/4885HDAC2 1389/4885HDAC8 975/4885 |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | HDAC1 1249/4885HDAC2 736/4885HDAC8 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.